Haleos Labs Limited

BSE: 540679 NSE: HALEOSLABS
Haleos Labs Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L74930TG2006PLC050223 Incorporated 31 May 2006 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: HALEOSLABS · BSE: 540679 Public Limited Company pharma
Data last updated
Market Cap
₹446 Cr
HALEOSLABS · NSE
Share Price
₹1,450.60
-1.59% today
Revenue
₹334 Cr
FY 2025-26 · -3.2% YoY
EBITDA
₹44.67 Cr
Margin 13.4%
Net Profit
₹17.30 Cr
FY 2025-26 · -13.9% YoY
P/E (TTM)
28.0x
P/B 2.1x
Authorised capital
₹3.5 Cr
Registered with MCA
Paid-up capital
₹3.02 Cr
Issued & subscribed

About Haleos Labs Limited

Data last updated:

Haleos Labs Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 31 May 2006 and has been in existence for over 20 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L74930TG2006PLC050223. Its GSTIN is 36AAECP4285F1ZB (Telangana). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 540679 and NSE: HALEOSLABS.

The company has an authorised share capital of ₹3.5 Cr and a paid-up capital of ₹3.02 Cr. It was formerly known as Potluri Real Estate Private Limtied and Potluri Packaging Industries Private Limited. It is led by directors including Veeravenkata Satyanarayana Murthy Talluri (Managing Director) and Venkata Praveen Talluri (Whole-Time Director).

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Plot No.19 – III Road No.71 Jubilee Hills Opp. Bharatiya Vidya Bhavan Public School, Hyderabad, Telangana, India – 500096.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹333.79 Cr, a decline of 3.2% compared to the previous year. For the same year it recorded a net profit of ₹17.3 Cr (net margin 5.2%) and EBITDA of ₹44.67 Cr (EBITDA margin 13.4%). The net worth stands at ₹213.54 Cr (up 8.6% YoY). Total assets are valued at ₹345.03 Cr (up 13.6% YoY).

The company has about 558 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: SMS LifeSciences. As per MCA filings, the company has open charges of ₹133.44 Cr and satisfied charges of ₹67.83 Cr on record. Court records list 3 cases involving the company, including 3 filed by the company; 1 case is pending. The company has 27 deals on record (27 market trades); the latest was in December 2025. Its 9 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Oneiro Lifecare Private Limited with revenue of ₹366.81 Cr.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website smslife.in.

Company details

CIN L74930TG2006PLC050223
Registration Number 050223
Incorporation Date 31 May 2006
ROC Hyderabad
Listing Status Listed - Listed on NSE (HALEOSLABS); Listed on BSE (540679)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Haleos Labs has undergone 4 name changes throughout its history. The current legal name is Haleos Labs Limited.

Company NameStatus
Haleos Labs LimitedCurrent
Potluri Real Estate Private LimtiedPrevious
Potluri Packaging Industries Private LimitedPrevious
Sms Lifesciences India Private LimitedPrevious

CIN history

Haleos Labs has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74930TG2006PLC050223, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L74930TG2006PLC050223Current
U74930TG2006PTC050223Previous
U45201AP2006PTC050223Previous
U74930AP2006PTC050223Previous
Key People
Veeravenkata Satyanarayana Murthy Talluri Managing Director Venkata Praveen Talluri Whole-Time Director Sudeepthi Gopineedi Whole-Time Director

Contact details

Haleos Labs Limited's registered office is in Hyderabad, Telangana. Its website is smslife.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    smslife.in
  • Registered Address
    Plot No.19 – III Road No.71 Jubilee Hills Opp. Bharatiya Vidya Bhavan Public School, Hyderabad, Telangana, India – 500096
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Haleos Labs Limited, buy the company report.

Comprehensive company report
Haleos Labs Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Haleos Labs operates one associated brand: SMS LifeSciences. Each brand links to its own profile.

BrandDescriptionWebsite
SMS LifeSciences
Active Pharmaceutical Ingredients and intermediates are manufactured for pharmaceuticals.smslife.in

Business activity

The main business activity of Haleos Labs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Haleos Labs Limited, buy the company report.

Financials of Haleos Labs Limited

FY 2025-26 filings available

Haleos Labs Limited reported revenue of ₹333.79 Cr (down 3.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹334 Cr
-3.2% YoY
EBITDA
₹44.67 Cr
-1.0% YoY
Profit After Tax
₹17.30 Cr
-13.9% YoY
Net Worth
₹214 Cr
+8.6% YoY
Total Assets
₹345 Cr
+13.6% YoY
Total Debt
₹111 Cr
+27.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue334345306316350266261
Revenue growth-3.2%+12.7%-3.0%-9.9%+31.8%+1.8%-
EBITDA44.6745.1031.2128.8034.5430.2425.40
EBITDA margin+13.4%+13.1%+10.2%+9.1%+9.9%+11.4%+9.7%
Profit before tax25.1826.199.8416.5632.7319.5614.67
Net profit17.3020.099.099.8715.8613.5310.15
Net profit margin+5.2%+5.8%+3.0%+3.1%+4.5%+5.1%+3.9%
EPS (₹)57.2666.5130.0837.9183.7644.8433.68
Balance sheet
Total assets345304299293248203183
Net worth214197177169152129116
Total debt11186.4010110079.6064.6964.59
Cash & bank2.371.511.494.414.3911.067.59
Net working capital66.5974.9175.9069.7957.9937.7447.12
Cash flow
Cash from operations37.2234.0524.3114.70(11.24)35.1714.55
Cash from investing(57.90)(15.00)(18.45)(31.29)(7.14)(26.23)(27.02)
Cash from financing21.38(19.12)(6.56)16.8910.83(2.55)12.45
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue72.9475.1494.7881.3782.5089.1184.6078.46
Revenue growth (YoY)-11.6%-15.7%+12.0%+3.7%-10.9%---
Other income0.462.010.180.421.002.340.062.04
EBITDA9.124.1614.0513.5711.717.4212.758.56
EBITDA margin+12.5%+5.5%+14.8%+16.7%+14.2%+8.3%+15.1%+10.9%
Depreciation4.243.853.913.893.823.803.763.76
Interest1.901.421.541.621.872.032.142.14
Profit before tax3.440.908.788.487.023.936.914.70
Tax1.600.562.132.072.640.452.061.40
Net profit1.840.346.656.414.383.484.853.30
EPS (₹)8.751.4421.8920.1913.759.8318.0815.46
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue301333300315346260257
Revenue growth-9.7%+11.1%-4.8%-8.8%+32.8%+1.3%-
EBITDA40.4744.2934.5426.4931.4329.7923.82
EBITDA margin+13.5%+13.3%+11.5%+8.4%+9.1%+11.5%+9.3%
Profit before tax25.2030.0419.1218.3932.9919.3413.36
Net profit17.7921.3513.0811.3615.9213.149.11
Net profit margin+5.9%+6.4%+4.4%+3.6%+4.6%+5.1%+3.6%
EPS (₹)58.8070.6943.2243.7283.9543.5630.26
Balance sheet
Total assets313283272255217180166
Net worth215197176164151126113
Total debt94.8081.5691.7486.9962.0744.8650.09
Cash & bank1.561.411.260.952.148.902.30
Net working capital10711611396.7576.7453.6546.92
Cash flow
Cash from operations38.4328.0314.754.58(14.66)21.6213.95
Cash from investing(49.28)(13.77)(13.75)(27.96)(7.49)(5.94)(13.28)
Cash from financing10.85(14.20)(0.82)22.5914.63(7.87)(2.05)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue67.8363.3880.7277.8479.0485.4382.8878.50
Revenue growth (YoY)-14.2%-25.8%-2.6%-0.8%-8.7%---
Other income0.460.970.080.441.012.200.061.26
Total expenses58.1857.1869.1667.0468.2179.8369.8166.70
EBITDA9.656.2011.5610.8010.835.6013.0711.80
EBITDA margin+14.2%+9.8%+14.3%+13.9%+13.7%+6.6%+15.8%+15.0%
Depreciation3.012.662.692.682.632.622.562.57
Interest1.811.341.461.511.731.841.961.92
Profit before tax5.293.177.497.057.483.348.618.57
Tax2.040.942.082.072.320.662.382.55

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue72.9475.1494.7881.3782.5089.1184.6078.46
Revenue growth (YoY)-11.6%-15.7%+12.0%+3.7%-10.9%---
Other income0.462.010.180.421.002.340.062.04
EBITDA9.124.1614.0513.5711.717.4212.758.56
EBITDA margin+12.5%+5.5%+14.8%+16.7%+14.2%+8.3%+15.1%+10.9%
Depreciation4.243.853.913.893.823.803.763.76
Interest1.901.421.541.621.872.032.142.14
Profit before tax3.440.908.788.487.023.936.914.70
Tax1.600.562.132.072.640.452.061.40
Net profit1.840.346.656.414.383.484.853.30
EPS (₹)8.751.4421.8920.1913.759.8318.0815.46
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue334345306316350266261
Revenue growth-3.2%+12.7%-3.0%-9.9%+31.8%+1.8%-
Other income2.434.863.835.4214.431.782.28
Total expenses289300275287316235235
Employee cost0.0059.5452.2643.4339.9030.6626.56
EBITDA44.6745.1031.2128.8034.5430.2425.40
EBITDA margin+13.4%+13.1%+10.2%+9.1%+9.9%+11.4%+9.7%
Depreciation15.4715.0014.9410.7910.017.867.86
Interest6.458.7710.266.876.234.605.15
Profit before tax25.1826.199.8416.5632.7319.5614.67
Tax7.397.463.525.227.436.024.49
Net profit17.3020.099.099.8715.8613.5310.15
Net profit margin+5.2%+5.8%+3.0%+3.1%+4.5%+5.1%+3.9%
EPS (₹)57.2666.5130.0837.9183.7644.8433.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital3.023.023.023.023.023.023.02
Reserves & surplus211194174166149126113
Shareholders' funds (net worth)214197177169152129116
Minority interest16.0115.4916.8219.6012.700.000.00
Secured loans10984.0197.7195.0472.3259.2658.27
Unsecured loans1.692.393.015.457.285.436.32
Total debt11186.4010110079.6064.6964.59
Total liabilities345304299293248203183
Assets
Gross block363313290281178164150
Net block268232223228142130124
Capital work in progress10.420.406.000.8551.1838.3115.76
Investments0.040.040.040.040.040.040.04
Inventories79.8267.4081.2186.2384.8161.6364.30
Sundry debtors61.3468.7951.3546.0633.8334.1521.61
Cash & bank balances2.371.511.494.414.3911.067.59
Loans & advances19.5712.8822.0322.4132.9819.4413.72
Total current assets163151156159156126107
Total current liabilities96.5175.6780.1889.3298.0288.5460.10
Net working capital66.5974.9175.9069.7957.9937.7447.12
Total assets345304299293248203183
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.500.571.280.998.542.152.17
Net cash from operating activities37.2234.0524.3114.70(11.24)35.1714.55
Net cash from investing activities(57.90)(15.00)(18.45)(31.29)(7.14)(26.23)(27.02)
Net cash from financing activities21.38(19.12)(6.56)16.8910.83(2.55)12.45
Net change in cash0.71(0.07)(0.71)0.29(7.55)6.39(0.03)
Closing cash2.371.511.494.414.3911.067.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-3.2%+12.7%-3.0%-9.9%+31.8%+1.8%-
EBITDA growth-1.0%+44.5%+8.4%-16.6%+14.2%+19.1%-
PBT growth-3.9%+166.2%-40.6%-49.4%+67.3%+33.3%-42.2%
Net income growth-13.9%+121.0%-7.9%-37.8%+17.2%+33.3%-
Revenue CAGR (3Y)+1.9%-0.5%+4.8%+6.6%-2.5%--
EBITDA CAGR (3Y)+15.8%+9.3%+1.1%+4.3%-0.2%--
Profitability & leverage
Net income margin+5.3%+5.4%+2.1%+3.6%+7.2%+5.1%+3.9%
Return on capital employed-+12.3%+7.2%+8.3%+12.0%+12.5%+11.7%
Return on net worth-+10.0%+3.7%+6.1%+11.3%+11.1%+9.2%
Debt / equity-0.500.580.560.510.530.50
Long-term debt / equity-0.230.310.310.290.310.29
Interest cover22.0929.1463.0638.1525.4020.5529.36
Efficiency & per share
Fixed asset turnover-1.281.191.562.271.882.03
Inventory turnover-5.194.054.195.314.693.99
Debtors turnover-6.436.968.9711.4410.599.23
EPS (₹)57.2666.5130.0837.9183.7644.8433.68
Dividend per share (₹)1.501.501.501.501.501.500.00
Book value per share (₹)0.00650.15584.84557.71503.53427.40382.80
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue67.8363.3880.7277.8479.0485.4382.8878.50
Revenue growth (YoY)-14.2%-25.8%-2.6%-0.8%-8.7%---
Other income0.460.970.080.441.012.200.061.26
Total expenses58.1857.1869.1667.0468.2179.8369.8166.70
EBITDA9.656.2011.5610.8010.835.6013.0711.80
EBITDA margin+14.2%+9.8%+14.3%+13.9%+13.7%+6.6%+15.8%+15.0%
Depreciation3.012.662.692.682.632.622.562.57
Interest1.811.341.461.511.731.841.961.92
Profit before tax5.293.177.497.057.483.348.618.57
Tax2.040.942.082.072.320.662.382.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue301333300315346260257
Revenue growth-9.7%+11.1%-4.8%-8.8%+32.8%+1.3%-
Other income1.423.953.845.2314.231.331.88
Total expenses261289265289314230233
Employee cost0.0045.7840.9234.7232.5127.1123.27
EBITDA40.4744.2934.5426.4931.4329.7923.82
EBITDA margin+13.5%+13.3%+11.5%+8.4%+9.1%+11.5%+9.3%
Depreciation10.6610.2610.258.177.997.217.24
Interest6.037.949.015.164.684.575.10
Profit before tax25.2030.0419.1218.3932.9919.3413.36
Tax7.418.676.045.167.606.194.19
Net profit17.7921.3513.0811.3615.9213.149.11
Net profit margin+5.9%+6.4%+4.4%+3.6%+4.6%+5.1%+3.6%
EPS (₹)58.8070.6943.2243.7283.9543.5630.26
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital3.023.023.023.023.023.023.02
Reserves & surplus212194173161148123110
Shareholders' funds (net worth)215197176164151126113
Secured loans93.1179.1788.7381.5454.7939.4343.77
Unsecured loans1.692.393.015.457.285.436.32
Total debt94.8081.5691.7486.9962.0744.8650.09
Total liabilities313283272255217180166
Assets
Gross block262213192184128131119
Net block19015013814098.7210194.50
Capital work in progress1.300.406.000.8521.213.162.47
Investments23.2323.2323.2323.2323.2425.8125.81
Inventories69.8160.5874.5980.4681.3658.7661.05
Sundry debtors54.2664.5349.3545.5233.7729.9922.02
Cash & bank balances1.561.411.260.952.148.902.30
Loans & advances56.0751.2850.1640.6645.0537.7715.84
Total current assets182178175168162135101
Total current liabilities74.2261.7762.5470.8485.5881.7754.29
Net working capital10711611396.7576.7453.6546.92
Total assets313283272255217180166
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.400.330.150.958.460.652.03
Net cash from operating activities38.4328.0314.754.58(14.66)21.6213.95
Net cash from investing activities(49.28)(13.77)(13.75)(27.96)(7.49)(5.94)(13.28)
Net cash from financing activities10.85(14.20)(0.82)22.5914.63(7.87)(2.05)
Net change in cash0.000.070.18(0.80)(7.52)7.81(1.38)
Closing cash1.561.411.260.952.148.902.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-9.7%+11.1%-4.8%-8.8%+32.8%+1.3%-
EBITDA growth-8.6%+28.2%+30.4%-15.7%+5.5%+25.1%-
PBT growth-16.1%+57.1%+4.0%-44.3%+70.6%+44.8%-43.8%
Net income growth-16.7%+63.2%+15.1%-28.6%+21.2%+44.2%-
Revenue CAGR (3Y)-1.5%-1.2%+4.9%+7.1%+0.1%+6.8%+5.7%
EBITDA CAGR (3Y)+15.2%+12.1%+5.1%+3.6%-1.1%+31.2%-5.7%
Profitability & leverage
Net income margin+5.9%+6.4%+4.4%+4.2%+7.4%+5.1%+3.6%
Return on capital employed-+13.7%+10.7%+8.9%+12.5%+13.8%+11.5%
Return on net worth-+11.5%+7.7%+7.2%+11.5%+11.0%+8.4%
Debt / equity-0.460.530.470.390.400.45
Long-term debt / equity-0.130.230.240.180.190.24
Interest cover20.2323.3337.0928.1719.9720.2430.76
Efficiency & per share
Fixed asset turnover-1.821.752.262.922.302.53
Inventory turnover-5.454.244.355.414.794.19
Debtors turnover-6.476.938.8811.8911.039.65
EPS (₹)58.8070.6943.2243.7283.9543.5630.26
Dividend per share (₹)1.501.501.501.501.501.500.00
Book value per share (₹)0.00652.19582.90542.55500.16417.88374.61

To see the full year-wise statements and ratios of Haleos Labs Limited, buy the company report.

Board of directors of Haleos Labs Limited

Haleos Labs has 6 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Veeravenkata Satyanarayana Murthy Talluri
Also directs: Mahi Drugs Private Limited
Managing Director01 Apr 201610 Years 6 MonthsCurrent
Sarath Kumar Pakalapati
Also directs: Mahi Drugs Private Limited, Shreyas Management and Services Private Limited
Director25 May 20179 Years 5 MonthsCurrent
Venkata Praveen Talluri
Also directs: Mahi Drugs Private Limited
Whole-Time Director21 Aug 20206 Years 2 MonthsCurrent
Sudeepthi GopineediWhole-Time Director02 Sep 20215 Years 1 MonthsCurrent
Srinivas Samavedam
Also directs: Hics Academy of Critical Care LLP, Crest Clinical Services Private Limited
Director13 Nov 20214 Years 11 MonthsCurrent
Mannam Malakondaiah
Also directs: Beardsell Limited, NSL Textiles Limited, NSL Sez (Hyderabad) Private Limited and 1 more
Director13 Nov 20214 Years 11 MonthsCurrent
View all directors

Peer comparison

Haleos Labs Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Oneiro Lifecare Private Limited₹366.81 Cr (FY 2025)14.0%Vadodara, Gujarat, India
Kopran Research Laboratories Limited₹365.89 Cr (FY 2025)13.0%Mumbai, Maharashtra, India
Zydus Takeda Healthcare Private Limited₹361.57 Cr (FY 2025)-54.0%Navi Mumbai, Maharashtra, India
R.L.Fine Chem Private Limited₹360.48 Cr (FY 2025)6.0%Bangalore, Karnataka, India
Vital Laboratories Private Limited₹357.13 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
SCL Lifesciences Limited₹340.47 Cr (FY 2025)-4.0%Punjab, India
Valiant Laboratories Limited₹338.77 Cr (FY 2023)61.0%Mumbai, Maharashtra, India
Haleos Labs Limitedthis company₹333.79 Cr (FY 2026)₹17.3 Cr5.2%-3.2%558Hyderabad, Telangana, India
Mehta Api Private Limited₹325.77 Cr (FY 2025)36.0%Mumbai, Maharashtra, India
Synergene Active Ingredients Private Limited₹319.93 Cr (FY 2024)37.0%Hyderabad, Telangana, India

To see the full peer comparison of Haleos Labs Limited, buy the company report.

Auditor

Haleos Labs Limited is audited by Rambabu & Co for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Rambabu & CoFY 2023002976S

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 72.10%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.30% and retail and other public shareholders hold 27.60%.

Promoters: 72.10%DII (Domestic Institutional): 0.30%Retail & Others: 27.60%
Sep 2026
QUARTER
72.10% Promoters
0.30% DII (Domestic Institutional)
27.60% Retail & Others
Promoter holding - history
Now 72.10% · Sep 2026High 72.10% · Jun 2026Low 71.40% · Dec 2025
70%71%72%73%74%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 71.40%Mar 2026: 71.80%Jun 2026: 72.10%Sep 2026: 72.10%72.10%71.40%72.10%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters72.10%72.10%71.80%71.40%
Public27.90%27.90%28.20%28.60%

Charges & borrowings

Open charges
₹133.44 Cr
Satisfied charges
₹67.83 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹100.00 Cr
Others₹33.44 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
12 Aug 2022100604717Hdfc Bank Limited₹30 CrOpen
31 Mar 2022100571180Hdfc Bank Limited₹70 CrOpen
29 Mar 2022100560259Others₹3.44 CrOpen
26 May 2017100100545Others₹30 CrOpen
16 Mar 2021100425999Others₹7.83 CrSatisfied

To see the full charge records of Haleos Labs Limited, buy the company report.

Total charge records: 8 View all charges

Deals & funding

Haleos Labs Limited has 27 deals on record (27 market trades); the latest was in December 2025.

Total deals
27
Market trades
27

Deals on record (5 of 27)

WhenDealAmountParties
Apr 2022Market trade₹5.31 CrBuyer: Indra Kiran Ventures, Bytes and Pixels Finsoft LLP
Seller: Bytes and Pixels Finsoft LLP , Indra Kiran Ventures, an individual
Jun 2021Market trade₹1.37 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Jun 2021Market trade₹4.01 CrBuyer: NK Securities Research Private Limited , Graviton Research Capital LLP
Seller: NK Securities Research Private Limited , Graviton Research Capital LLP
Dec 2020Market trade₹6.54 CrBuyer: an individual
Seller: Potluri Infra Projects LLP
Nov 2020Market trade₹5.14 CrBuyer: an individual
Seller: Potluri Laboratories Private Limited , Potluri Infra Projects LLP

To see the full deal history of Haleos Labs Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Haleos Labs Limited was last rated by Care on 28 Sep 2022.

Rating agencyRated onRating
Care28 Sep 2022

To see the full credit ratings and regulatory alerts of Haleos Labs Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Haleos Labs Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Group structure & subsidiaries

Haleos Labs has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Mahi Drugs Private LimitedU24233AP2012PTC084875

To see the full group structure of Haleos Labs Limited, buy the company report.

Employees & EPFO

Haleos Labs Limited has a workforce of 558 employees on its EPFO records as of Mar 22, 2024, across 3 active EPFO establishments.

Employee count
558
Active EPFO establishments
3
Employee growth
-0.71%

GST

Haleos Labs has 2 GST registrations: 1 active and 1 cancelled or inactive.

Total GSTINs
2
Active
1
Cancelled / inactive
1
GSTINStateStatusRegistered on
36AAECP4285F1ZBTelanganaActive01 Jul 2017

To see the full GST registrations and return filing status of Haleos Labs Limited, buy the company report.

Recent activity

Haleos Labs Limited has 21 board changes on record since 2006: 14 appointments and 7 cessations. The latest: Sundaramma Patibandla was appointed as Director on 12 Feb 2025.

Charges
A charge registered on 25 Sep 2018 via Charge ID 100206545 with Others was fully satisfied on 16 Jun 2026.
Filing
Haleos Labs Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Charges
A charge with Hdfc Bank Limited of Rs. 70.00 Cr registered on 31 Mar 2022 with Charge ID 100571180 was modified on 23 Jan 2026.
AGM
Haleos Labs Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge registered on 16 Mar 2021 via Charge ID 100425999 with Others was fully satisfied on 20 Aug 2025.
Appointed
Sundaramma Patibandla was appointed as Director.
Charges
A charge with Others of Rs. 30.00 Cr registered on 26 May 2017 with Charge ID 100100545 was modified on 05 Mar 2024.
Charges
A charge with Hdfc Bank Limited of Rs. 30.00 Cr registered on 12 Aug 2022 with Charge ID 100604717 was modified on 20 Feb 2023.
Ceased
Venkatasubbarao Potluri ceased to be Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 30.00 Cr with Charge ID 100604717 was registered on 12 Aug 2022.
Charges
A charge with Others of Rs. 3.44 Cr registered on 29 Mar 2022 with Charge ID 100560259 was modified on 29 Jun 2022.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 70.00 Cr with Charge ID 100571180 was registered on 31 Mar 2022.

30 earlier events are in the company report.

News

Frequently asked questions

Haleos Labs is an active public limited company based in Hyderabad, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 31 May 2006 (20+ years old) and is registered under CIN L74930TG2006PLC050223. Listed on BSE: 540679 and NSE: HALEOSLABS.

Haleos Labs reported revenue of ₹333.79 Cr for FY 2025-26 (down 3.2% YoY) based on consolidated financials.

Haleos Labs has 6 current directors:

The latest financial statements of Haleos Labs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Haleos Labs is 36AAECP4285F1ZB, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.

The CIN (Corporate Identification Number) of Haleos Labs is L74930TG2006PLC050223. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Haleos Labs is a listed company as per MCA records. Its shares are listed on both BSE (code: 540679) and NSE (symbol: HALEOSLABS).

Haleos Labs has 3 court cases on record: 3 filed by the company. 1 is pending.

Haleos Labs was incorporated on 31 May 2006, making it 20+ years old. It is registered with the Registrar of Companies, Hyderabad.

Haleos Labs has 27 deals on record (27 market trades); the latest was in December 2025.

The peers of Haleos Labs by revenue are Oneiro Lifecare Private Limited, Kopran Research Laboratories Limited, Zydus Takeda Healthcare Private Limited, R.L.Fine Chem Private Limited, Vital Laboratories Private Limited and 4 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).